1. A model for in situ plan of care for a critically unstable pediatric patient following I-131 MIBG infusion.
- Author
-
Flori HR, Mwenesi R, Scott A, Conrad CM, Quinn JA, Ostwani W, Fischer KW, and Yanik GA
- Subjects
- 3-Iodobenzylguanidine administration & dosage, Child, Critical Care standards, Critical Illness epidemiology, Female, Humans, Infusions, Intravenous, Iodine Radioisotopes administration & dosage, Michigan epidemiology, Prognosis, Radiopharmaceuticals administration & dosage, Radiopharmaceuticals adverse effects, Radiotherapy Dosage, 3-Iodobenzylguanidine adverse effects, Critical Illness therapy, Iodine Radioisotopes adverse effects, Models, Statistical, Neuroblastoma radiotherapy, Patient-Centered Care standards, Radiation Exposure standards
- Abstract
Recent clinical trials have moved iodine-131 (I-131) metaiodobenzylguanidine (MIBG) therapy into frontline management of high-risk neuroblastoma. With this expansion, it is reasonable to anticipate the need for intensive care level resuscitations. Radiation exposure remains the greatest risk to health care professionals managing these patients. We combined shock simulation scenario data with actual radiation dosimetry data to create a care model allowing for aggressive, prolonged in situ resuscitation of a critically ill pediatric patient after I-131 MIBG administration. This model will maintain a critical care provider's radiation level below 10% of the annual occupational dose limit (5 mSv, 500 mrem) per patient managed., (© 2020 Wiley Periodicals LLC.)
- Published
- 2020
- Full Text
- View/download PDF